TOP TEN perturbations for 39701_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39701_at
Selected probe(set): 209242_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39701_at (209242_at) across 6674 perturbations tested by GENEVESTIGATOR:
Hep-G2 / HepaRG
Relative Expression (log2-ratio):9.599007Number of Samples:9 / 12
| Experimental | Hep-G2 |
| Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code: | |
| Control | HepaRG |
| Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code: |
bone cancer study 1 (PDX; osteosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):-7.5150023Number of Samples:2 / 2
| Experimental | bone cancer study 1 (PDX; osteosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted). | |
| Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |
bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; osteosarcoma, NOS; primary)
Relative Expression (log2-ratio):6.9297314Number of Samples:2 / 2
| Experimental | bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted). | |
| Control | bone cancer study 1 (PDX; osteosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted). |
expO ovary cancer study 1 (serous surface papillary carcinoma; metastatic) / expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Relative Expression (log2-ratio):-6.647191Number of Samples:2 / 2
| Experimental | expO ovary cancer study 1 (serous surface papillary carcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary serous surface papillary carcinoma of the ovary. | |
| Control | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. |
myotonic dystrophy study 4 (biceps brachii; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-6.4139175Number of Samples:9 / 3
| Experimental | myotonic dystrophy study 4 (biceps brachii; DM-like) |
| Biceps brachii biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Relative Expression (log2-ratio):-6.409794Number of Samples:8 / 2
| Experimental | expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary. | |
| Control | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. |
expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; metastatic)
Relative Expression (log2-ratio):6.3094215Number of Samples:2 / 4
| Experimental | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. | |
| Control | expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary clear cell adenocarcinoma (NOS) of the ovary. |
myotonic dystrophy study 4 (deltoid muscle; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-6.2026844Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM-like) |
| Deltoid muscle biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (skeletal muscle; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-6.0723066Number of Samples:8 / 3
| Experimental | myotonic dystrophy study 4 (skeletal muscle; DM2) |
| Unspecified skeletal muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (deltoid muscle; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-5.8780727Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM2) |
| Deltoid muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |